Shingles is not an autoimmune disease. It is caused by the reactivation of varicella zoster virus (VZV), the same virus responsible for chickenpox, which lies dormant in nerve tissue for years or decades after the initial infection. The confusion is understandable, though, because shingles is deeply tangled up with the immune system in ways that go well beyond a typical infection. People with autoimmune diseases get shingles at far higher rates, the drugs used to treat autoimmune conditions can trigger it, and shingles itself can sometimes kick off autoimmune reactions in the body. The relationship runs in several directions at once, but the disease itself remains fundamentally viral.
How Shingles Actually Develops
After a person recovers from chickenpox, VZV does not leave the body. It retreats into clusters of nerve cells called sensory ganglia, particularly the trigeminal and dorsal root ganglia along the spine, and enters a dormant state known as latency.1PubMed. Varicella-zoster virus latency in human ganglia In this state the virus is not assembling new viral particles or causing symptoms. It persists quietly, with only a small number of viral genes still active. Research using human nerve tissue transplanted into immunodeficient mice has shown that VZV can establish and maintain this latent state without any help from the immune system at all. The virus essentially parks itself in a location where the body’s immune surveillance is limited.2PubMed Central. Varicella-zoster virus infection of human dorsal root ganglia in vivo
When the immune system weakens, VZV can wake up. It begins replicating again, traveling along nerve fibers to the skin and producing the painful, blistering rash that characterizes shingles. This reactivation is driven by a decline in the specific arm of immunity that keeps VZV in check: cell-mediated immunity, the part of the immune response involving T cells rather than antibodies.3PubMed Central. Clinical and molecular aspects of varicella zoster virus infection In an autoimmune disease, the immune system mistakenly attacks the body’s own healthy tissue. In shingles, the problem is the opposite: the immune system is failing to do its job of suppressing a real pathogen.
Why the Immune System Gets So Much of the Blame
The reason shingles gets lumped in with immune disorders in casual conversation is that immune decline is the central trigger. In healthy young adults, VZV-specific T cells patrol the body and keep the virus locked down. As people age, those T cell responses weaken substantially. CD8+ T cells in particular show a loss of diversity and stem-like features in older adults, which leaves them less capable of controlling VZV.4PubMed Central. Antigen-specific TH17 cells offset the age-related decline in durable T cell immunity This age-related immune decline is the primary reason shingles overwhelmingly affects people over 50.
VZV also has some clever tricks for suppressing immune responses. Research has shown that the virus triggers early antiviral signaling in infected cells, including production of interferons, but then ramps up expression of a protein called SOCS3 that dials those defenses back down in later stages of infection.5PubMed. Suppressor of Cytokine Signaling 3 Expression Induced by Varicella-Zoster Virus Infection Results in the Modulation of Virus Replication This is a viral strategy for evading innate immunity, not an autoimmune process. The virus is actively undermining the defenses that should be containing it.
So shingles sits in an unusual space: it is caused by a virus, but its timing and severity are dictated almost entirely by immune function. That dependence on immune status is why people with genuinely autoimmune conditions face an outsized risk.
Autoimmune Diseases Dramatically Raise Shingles Risk
If you have an autoimmune disease, your chances of developing shingles are meaningfully higher than average. The general population in the United States develops shingles at a rate of roughly 1.5 to 3 cases per 1,000 people per year. In people with systemic lupus erythematosus (lupus), that rate jumps to somewhere between 6 and 32 per 1,000 person-years, depending on the study and the population examined.6PubMed Central. Herpes zoster in patients with systemic lupus erythematosus: Clinical features, complications and risk factors That is a range of roughly two to ten times the normal rate, which is a substantial elevation.
The increased risk comes from two directions. First, autoimmune diseases themselves involve a dysregulated immune system. The body is busy attacking its own tissues, and the resulting immune dysfunction can weaken its ability to keep VZV suppressed. Second, the medications used to manage autoimmune diseases often suppress the immune system deliberately, which has the side effect of loosening the body’s grip on dormant viruses. A large meta-analysis of lupus patients identified several treatment-related risk factors for shingles:
- Glucocorticoids: roughly tripled the risk of shingles
- Cyclophosphamide: about two and a half times the risk
- Mycophenolate mofetil: tripled the risk
- Having low lymphocyte counts (lymphopenia): more than doubled the risk
Kidney involvement in lupus also independently raised the risk by about 80%.7Frontiers in Immunology. Prevalence, incidence, and risk factors for herpes zoster in systemic lupus erythematosus: a systematic review and meta-analysis The pattern is consistent: the more immunosuppressed you are, whether from the disease itself or its treatment, the more likely VZV is to escape dormancy.
JAK Inhibitors and the Shingles Connection
A newer class of drugs has brought the shingles-autoimmunity link into sharper focus. JAK inhibitors, which target intracellular signaling pathways involved in immune function, are now widely used for rheumatoid arthritis, psoriasis, inflammatory bowel disease, and atopic dermatitis. These drugs are effective precisely because they dampen immune signaling, but that same mechanism appears to open the door for VZV reactivation.8PubMed Central. JAK inhibitors and infections risk: focus on herpes zoster
A systematic review comparing different JAK inhibitors found that several carried a clearly elevated shingles risk compared to placebo. Higher doses tended to carry higher risk. For instance, upadacitinib at its higher dose was associated with about a threefold increase, while tofacitinib at its higher dose roughly doubled the risk.9PubMed Central. Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis This has become a significant clinical concern. If you are starting a JAK inhibitor, your doctor will likely discuss shingles vaccination beforehand, because once you are on the medication, your vulnerability window is open.
The JAK pathway is directly involved in how cells respond to interferons, the signaling molecules that serve as a first line of defense against viruses. When you inhibit JAK signaling, you are not just suppressing the autoimmune inflammation you are trying to treat. You are also weakening one of the body’s primary antiviral alarm systems. VZV, already skilled at evading innate immunity, gets an even easier path to reactivation.
When Shingles Triggers Autoimmune-Like Reactions
Here is where the question gets more interesting. Shingles is not an autoimmune disease, but VZV infection can sometimes provoke the immune system into producing autoantibodies, which are antibodies that target the body’s own proteins. A study of children with acute VZV infection (chickenpox, in this case) found a significantly elevated frequency of autoantibodies directed against phospholipids and coagulation proteins compared to uninfected children. These autoantibodies appeared transiently and were not associated with actual blood clotting complications, but they demonstrate that VZV can nudge the immune system toward self-reactive responses.10Pediatric Research. The Varicella-Autoantibody Syndrome
The broader phenomenon of viruses triggering autoimmune processes is well-documented. Multiple mechanisms have been proposed for how viral infections can set off autoimmunity, including molecular mimicry, where viral proteins resemble the body’s own proteins closely enough that the immune response accidentally targets both. Herpesviruses as a family are among the best-studied examples of viruses that may modulate autoimmune disease development.11PubMed Central. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms This does not mean that shingles causes autoimmune disease in most people. It means that in susceptible individuals, the immune disruption caused by VZV reactivation can occasionally tip the balance.
Shingles and Guillain-Barré Syndrome
One of the clearest examples of VZV triggering an autoimmune-like complication is Guillain-Barré syndrome (GBS), a condition in which the immune system attacks the peripheral nerves, causing weakness and sometimes paralysis. GBS is rare after shingles, but the association is real and has been documented in case reports and case series spanning decades.12PubMed. Guillain-Barré syndrome after varicella-zoster infection. Report of two cases
VZV-associated GBS appears to involve a specific form of the syndrome. In a study of over 500 GBS patients, about 1.3% had experienced chickenpox or shingles in the weeks before onset. All of these VZV-associated cases showed demyelination, meaning the immune attack stripped away the protective myelin coating around nerves rather than damaging the nerve fibers themselves. This demyelinating pattern was distinct from the axonal form of GBS more commonly triggered by other infections.13PubMed. Guillain-Barré syndrome following varicella-zoster virus infection VZV-triggered GBS remains uncommon, but it illustrates how a fundamentally viral disease can have genuinely autoimmune consequences in a small number of people.
Vascular Complications and Stroke Risk
Shingles can also affect blood vessels in the brain, a condition called VZV vasculopathy. When VZV reactivates and reaches cerebral arteries, it can directly infect the vessel walls, causing inflammation and structural remodeling that raises the risk of stroke. Multiple case reports and studies have confirmed this link.14PubMed Central. The relationship between herpes zoster and stroke This is not an autoimmune mechanism in the classical sense; the virus is physically present in the vessel walls and causing direct damage. But the resulting inflammatory process can blur the line, because the immune response to the virus within the vessels contributes to the vascular injury.
VZV vasculopathy is most concerning when shingles involves the ophthalmic branch of the trigeminal nerve (the form that affects the forehead and eye area), because those nerve fibers run close to the cerebral blood supply. The risk of stroke appears to be highest in the weeks and months immediately following a shingles episode and declines over time. This is another reason clinicians take shingles seriously beyond the rash and acute pain: the systemic consequences can be significant.
Postherpetic Neuralgia and Lasting Nerve Damage
The most common lasting complication of shingles is postherpetic neuralgia (PHN), a chronic pain condition that persists three months or longer after the rash clears. PHN involves persistent neuropathic pain that can take several forms: a constant deep burning or aching, sudden shooting pains, or an exaggerated pain response to stimuli that would not normally hurt, such as clothing brushing against the skin.15Current Pain and Headache Reports. Post-herpetic Neuralgia: a Review
PHN is not autoimmune either, but it sometimes gets mistaken for one because of how it behaves. The pain persists long after the virus has stopped actively replicating, which makes it seem like the body is attacking itself. What is actually happening is nerve damage: VZV destroys or injures sensory nerve fibers during the acute infection, and the damaged nerves continue sending abnormal pain signals long after the original cause is gone. The distinction matters because the treatments are different. PHN responds to neuropathic pain medications and nerve-targeted therapies, not to immune-suppressing drugs.
Stress as a Reactivation Trigger
One factor that feeds the “shingles is autoimmune” misconception is the well-known association between stress and shingles outbreaks. People often notice that their shingles appeared during or after a period of intense psychological stress, which sounds like the kind of mind-body connection associated with autoimmune flares. There is real data behind this observation. A large population-based cohort study found that people with high levels of perceived stress had an elevated risk of developing shingles. The risk increase was modest at moderate stress levels but climbed steeply at the high end: people with the highest stress scores had roughly double the risk of those with low stress.16PubMed Central. Perceived psychological stress and risk of herpes zoster: a nationwide population‐based cohort study
The mechanism is immunological, not autoimmune. Chronic psychological stress is known to suppress cell-mediated immunity, the same arm of the immune system that keeps VZV dormant. When stress hormones like cortisol stay elevated for extended periods, T cell function declines, and the virus gets an opportunity to reactivate. The experience of “my stress caused my shingles” is essentially correct, but the pathway runs through immune suppression, not immune misdirection.
Vaccination for People With Autoimmune Conditions
The recombinant zoster vaccine (Shingrix) has been a significant advance for people with autoimmune diseases. Unlike the older live vaccine (Zostavax), Shingrix does not contain live virus, which means it can be given to immunosuppressed patients. It works by targeting a specific viral surface protein called glycoprotein E, and it generates strong, long-lasting T cell responses that outperform the older vaccine’s immune boost.17PubMed Central. Immune responses to zoster vaccines After vaccination, the immune response is redirected to focus on this glycoprotein E target rather than the broader range of viral proteins recognized after natural infection.18PubMed Central. Identification and Characterization of CD4(+) T Cell Epitopes after Shingrix Vaccination
However, there is a genuine concern about disease flares. An analysis of adverse event reports found that about 8.5% of autoimmune disease patients who received Shingrix experienced a disease flare afterward. The risk varied by condition: lupus patients had the highest flare signal, followed by multiple sclerosis and rheumatoid arthritis. Most flares occurred within three days of vaccination.19PubMed Central. Risk of autoimmune disease flares after recombinant zoster vaccine: A vaccine safety analysis based on the Vaccine Adverse Event Reporting System database This does not mean the vaccine is unsafe for these patients, since the alternative, getting shingles while immunosuppressed, carries its own serious risks. But it does mean that timing the vaccine carefully, ideally during a stable disease period and in coordination with your rheumatologist, is worth the conversation.
The flare risk also underscores why the shingles-autoimmunity relationship confuses people. A vaccine that prevents a viral disease can temporarily worsen an autoimmune condition, which makes it feel like the two are somehow the same category of problem. They are not. The vaccine is stimulating an immune response, and in people whose immune systems are already prone to overreaction, that stimulation can briefly spill over into autoimmune territory. The virus and the autoimmune disease remain separate entities sharing the same immune system as a battleground.
How VZV Compares to Other Herpesviruses
VZV is part of a large family of herpesviruses, all of which establish lifelong latency after initial infection. Epstein-Barr virus (EBV), which causes mononucleosis, has drawn particularly intense attention for its potential role in triggering autoimmune diseases, most prominently multiple sclerosis. Large epidemiological studies have found a strong association between prior EBV infection and MS risk. VZV has not been linked to autoimmune disease causation with anywhere near the same strength. Its primary complication is reactivation as shingles rather than the initiation of a new autoimmune condition.
That said, both viruses share the strategy of hiding in immune-privileged sites where the body’s surveillance is limited. EBV persists in B cells; VZV persists in neurons. Both can flare when immune control weakens. The difference is that EBV appears to be capable of fundamentally reprogramming certain immune cells in ways that promote autoimmunity, while VZV’s autoimmune-adjacent effects, like transient autoantibodies or rare GBS cases, tend to be secondary consequences of the infection rather than the virus actively driving an autoimmune process. Researchers continue to investigate whether VZV might play a contributory role in certain neurological autoimmune conditions, but the evidence so far does not put it in the same category as EBV.